Wells Fargo’s Eledon Pharmaceuticals ELDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $295K | Buy |
74,944
+38,375
| +105% | +$140K | ﹤0.01% | 4954 |
|
|
2026
Q1 | $113K | Sell |
36,569
-32,337
| -47% | -$76.2K | ﹤0.01% | 5045 |
|
|
2025
Q4 | $104K | Buy |
68,906
+20,354
| +42% | +$48.4K | ﹤0.01% | 5376 |
|
|
2025
Q3 | $126K | Buy |
48,552
+11,396
| +31% | +$33.3K | ﹤0.01% | 5194 |
|
|
2025
Q2 | $101K | Buy |
+37,156
| New | +$111K | ﹤0.01% | 5191 |
|
|
2024
Q2 | – | Sell |
-189
| Closed | -$389 | – | 7050 |
|
|
2024
Q1 | $389 | Buy |
189
+3
| +2% | +$5 | ﹤0.01% | 6336 |
|
|
2023
Q4 | $335 | Buy |
186
+14
| +8% | +$19 | ﹤0.01% | 6474 |
|
|
2023
Q3 | $236 | Buy |
172
+26
| +18% | +$35 | ﹤0.01% | 6544 |
|
|
2023
Q2 | $200 | Buy |
146
+60
| +70% | +$125 | ﹤0.01% | 6704 |
|
|
2023
Q1 | $203 | Buy |
86
+2
| +2% | +$5 | ﹤0.01% | 6771 |
|
|
2022
Q4 | $192 | Buy |
84
+2
| +2% | +$5 | ﹤0.01% | 6630 |
|
|
2022
Q3 | $0 | Sell |
82
-10
| -11% | -$32 | ﹤0.01% | 6809 |
|
|
2022
Q2 | $0 | Buy |
92
+4
| +5% | +$12 | ﹤0.01% | 6957 |
|
|
2022
Q1 | $0 | Hold |
88
| – | – | ﹤0.01% | 7223 |
|
|
2021
Q4 | $0 | Hold |
88
| – | – | ﹤0.01% | 7342 |
|
|
2021
Q3 | $1K | Sell |
88
-4
| -4% | -$28 | ﹤0.01% | 6691 |
|
|
2021
Q2 | $1K | Sell |
92
-1
| -1% | -$9 | ﹤0.01% | 6649 |
|
|
2021
Q1 | $1K | Buy |
93
+85
| +1,063% | +$1.28K | ﹤0.01% | 6709 |
|
|
2020
Q4 | $0 | Buy |
8
+3
| +60% | +$57 | ﹤0.01% | 6588 |
|
|
2020
Q3 | $0 | Buy |
5
+1
| +25% | +$10 | ﹤0.01% | 6438 |
|
|
2020
Q2 | $0 | Hold |
4
| – | – | ﹤0.01% | 6390 |
|
|
2020
Q1 | $0 | Buy |
+4
| New | +$38 | ﹤0.01% | 6325 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 6206 |
|
|
2016
Q2 | – | Sell |
-2
| Closed | -$2.21K | – | 6147 |
|
|
2016
Q1 | $1K | Buy |
+2
| New | +$1.96K | ﹤0.01% | 6092 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 6263 |
|
|
2015
Q3 | – | Sell |
-3
| Closed | -$6.18K | – | 6055 |
|
|
2015
Q2 | $6K | Sell |
3
-3
| -50% | -$5.8K | ﹤0.01% | 5953 |
|
|
2015
Q1 | $11K | Buy |
+6
| New | +$13.2K | ﹤0.01% | 5591 |
|
Other funds holding ELDN
Wells Fargo's ELDN Position: Q2 2026 in Review
Wells Fargo increased its Eledon Pharmaceuticals (ELDN) stake by 105% in Q2 2026, buying an estimated $140K and bringing the position to 74,944 shares worth $295K. The position accounts for ﹤0.01% of the portfolio, ranked #4954.
Wells Fargo first reported a position in ELDN in Q1 2015 and has held it in 25 quarters since. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.
- Wells Fargo held 74,944 shares of Eledon Pharmaceuticals worth $295K as of Q2 2026.
- Wells Fargo bought 38,375 Eledon Pharmaceuticals shares in Q2 2026, an estimated $140K.
- Eledon Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4954 holding.
- Wells Fargo first reported a position in Eledon Pharmaceuticals in Q1 2015 and has held it in 25 quarters since.
- 161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.